Yoga for Painful Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized-Controlled Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-≥18 years of age,
- self-report ≥ 4/10 worst chemotherapy-induced peripheral neuropathy pain over the past week,
- at least three months post neurotoxic chemotherapy completion
- signed informed consent,
- willingness to participate in all study activities
- speak/read English
Exclusion Criteria:
- prognosis of less than three months,
- documented peripheral neuropathy due to other causes (e.g., diabetes),
- planned receipt of neurotoxic chemotherapy during the study period,
- practice yoga >45 minutes per week over the past six months,
- diagnosis or documented recent history of significant psychiatric comorbidity (i.e., psychosis, suicidal ideation, or substance abuse)
- clinician deems that the patient is physically/functionally unable to participate in a yoga program
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Yoga Program
Eight-weeks, therapist and self-guided yoga
|
Participants will attend at least one group class per week (in-person or Zoom) and practice one self-guided yoga video class at home on their own per week, over eight weeks Participants may choose to attend "Flow Yoga" and/or "Chair Flow Yoga" classes. These classes will be videotaped and made available to participants electronically. Classes consist of:
|
|
No Intervention: Treatment as usual
Control group participants will continue to receive usual care and symptom management strategies from clinicians during the study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants recruited to participate in the study
Time Frame: From enrollment to end of treatment at 8 weeks.
|
Feasibility of participant recruitment to the study
|
From enrollment to end of treatment at 8 weeks.
|
|
Frequency of yoga practice by participants
Time Frame: From enrollment to end of treatment at 8 weeks.
|
Feasibility of participant adherence to the yoga intervention
|
From enrollment to end of treatment at 8 weeks.
|
|
Frequency of outcome assessments completed by participants.
Time Frame: From enrollment to end of treatment at 8 weeks.
|
Feasibility of participant adherence to outcome assessments
|
From enrollment to end of treatment at 8 weeks.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptability and Satisfaction with Participation in Yoga Intervention
Time Frame: At the end of treatment, 8 weeks after enrollment
|
We will use semi-structured interviews to gain information about participants' experience with the yoga program
|
At the end of treatment, 8 weeks after enrollment
|
|
Worst Chemotherapy-Induced Peripheral Neuropathy Pain Intensity
Time Frame: At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
Change in 0 - 10 numerical rating scale of worst chemotherapy-induced peripheral neuropathy pain (via 7-day pain diary) from enrollment to end of treatment at 8 weeks.
Total scores range from 0 - 10, with higher scores representing worse pain.
|
At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
|
Chemotherapy-Induced Peripheral Neuropathy Severity
Time Frame: From enrollment to end of treatment at 8 weeks.At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
Change in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale-20 score from enrollment to end of treatment at 8 weeks.
Total scores range from 0 - 100, with higher scores representing worse chemotherapy-induced peripheral neuropathy severity.
|
From enrollment to end of treatment at 8 weeks.At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
|
Pain Interference
Time Frame: At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
Change in Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference 4a score from enrollment to the end of treatment at 8 weeks.
Total scores range from 41.6 - 75.6, with higher scores representing worse pain interference.
|
At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
|
Sleep-Related Impairment
Time Frame: At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
Change in Patient Reported Outcomes Measurement Information System (PROMIS) Sleep-related Impairment 8a score from enrollment to the end of treatment at 8 weeks.
Total scores range from 30.0 - 80.1 with higher scores representing worse sleep-related impairment.
|
At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
|
Anxiety assessed by the "Change in Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety"
Time Frame: At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
Change in Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a score from enrollment to the end of treatment at 8 weeks.
Total scores range from 40.3 - 81.6, with higher scores representing worse anxiety.
|
At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
|
Depression assessed by Change in Patient Reported Outcomes Measurement Information System (PROMIS) Depression
Time Frame: At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
Change in Patient Reported Outcomes Measurement Information System (PROMIS) Depression 4a score from enrollment to the end of treatment at 8 weeks.
Total scores range from 41.0 - 79.4, with higher scores representing worse depression.
|
At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
|
Fatigue assessed by Change in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue
Time Frame: At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
Change in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue 4a score from enrollment to the end of treatment at 8 weeks.
Total scores range from 33.7 - 75.8, with higher scores representing worse fatigue.
|
At the time of enrollment and at the end of treatment, 8 weeks after enrollment
|
|
Physical Function
Time Frame: At the time of enrollment and at the end of treatment, at 8 weeks.
|
Change in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function 4a score from enrollment to the end of treatment at 8 weeks.
Total scores range from 22.5 - 57.0, with higher scores representing better physical function.
|
At the time of enrollment and at the end of treatment, at 8 weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Robert Knoerl, PhD, Dana-Farber Cancer Institute
Publications and helpful links
General Publications
- Knoerl R, Giobbie-Hurder A, Berfield J, Berry D, Meyerhardt JA, Wright AA, Ligibel JA. Yoga for chronic chemotherapy-induced peripheral neuropathy pain: a pilot, randomized controlled trial. J Cancer Surviv. 2022 Aug;16(4):882-891. doi: 10.1007/s11764-021-01081-z. Epub 2021 Sep 15.
- Knoerl R, Phillips CS, Berfield J, Woods H, Acosta M, Tanasijevic A, Ligibel J. Lessons learned from the delivery of virtual integrative oncology interventions in clinical practice and research during the COVID-19 pandemic. Support Care Cancer. 2021 Aug;29(8):4191-4194. doi: 10.1007/s00520-021-06174-0. Epub 2021 Mar 26.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 18-578
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.